A detailed history of Hm Payson & CO transactions in Immuno Gen, Inc. stock. As of the latest transaction made, Hm Payson & CO holds 810 shares of IMGN stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
810
Previous 810 -0.0%
Holding current value
$0
Previous $12,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 06, 2023

SELL
$14.09 - $19.87 $47,328 - $66,743
-3,359 Reduced 80.57%
810 $12,000
Q2 2023

Jul 17, 2023

BUY
$3.75 - $20.05 $12,596 - $67,347
3,359 Added 414.69%
4,169 $78,000
Q2 2019

Aug 15, 2019

BUY
$1.8 - $3.3 $1,458 - $2,673
810 New
810 $2,000
Q1 2019

Jul 31, 2019

SELL
$2.41 - $5.91 $1,952 - $4,787
-810 Closed
0 $0
Q4 2018

Feb 15, 2019

BUY
$3.94 - $9.7 $3,191 - $7,856
810 New
810 $4,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Hm Payson & CO Portfolio

Follow Hm Payson & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hm Payson & CO, based on Form 13F filings with the SEC.

News

Stay updated on Hm Payson & CO with notifications on news.